Werewolf Therapeutics Announces Clinical Data for WTX-124 and WTX-330
Werewolf Therapeutics reported new clinical data for its WTX-124 and WTX-330 programs and confirmed alignment with the FDA on a recommended phase two dose for WTX-124.
Stocks · News reference
Filed: 2026-11-09 AccNo: 0001193125-26-452789 Size: 176 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Werewolf Therapeutics reported new clinical data for its WTX-124 and WTX-330 programs and confirmed alignment with the FDA on a recommended phase two dose for WTX-124.
Werewolf Therapeutics, Inc. is scheduled to release its financial results for the third quarter of 2026 on November 5, 2026.
Werewolf Therapeutics, Inc. announced its selection to present clinical and scientific data at the Society for Immunotherapy of Cancer's (SITC) 2026 Annual Meeting.
Law firm Brodsky & Smith announced investigations into four major merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and ensure fair value for shareholders. The investigations involve Personalis (acquired by Tempus AI for $16.25/share), Werewolf Therapeutics (acquired by Ambros Therapeutics), Beazer Homes (acquired by Dream Finders Homes for $33.50/share), and MarketAxess Holdings (acquired by Intercontinental Exchange for $167/share).
Dow gains 400 points, Materials sector up 2.3%, Werewolf Therapeutics up 113%, S&P PMI rises to strongest level since April 2022.